Do you want to read an article? Please log in or register.
Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences
Further Publications
RECOMMENDED
Related content
Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial
Read the comment: Effectiveness trials in asthma: time to SaLSA? >>>
doi: 10.1016/
RECOMMENDED
COPD
Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups
Respir Med.
Bakerly ND, Woodcock A,
Collier S, Leather DA, New JP,
Crawford J, Harvey C, Vestbo J,
Boucot I
doi: 10.1016/j.rmed.2018.12.016.
COPD
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
Respir Res.
Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA
doi: 10.1186/s12931-018-0724-0.
COMMENTED
Feasibility, acceptability and effectiveness of integrated care for COPD patients: a mixed methods evaluation of a pilot community-based programme
Swiss Med Wkly.
Carron T, Bridevaux PO, Lörvall K, Parmentier R, Moix JB, Beytrison V, Pernet R, Rey C, Roberfroid PY, Chhajed PN, Dieterle T, Joos Zellweger L, Kohler M, Maier S, Miedinger D, Thurnheer R, Urwyler P, Tschopp JM, Zuercher E, Leuppi JD, Burnand B, Peytremann-Bridevaux I
doi: 10.4414/smw.2017.14567.
RECOMMENDED
COPD
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, Lomas DA, Martin N, Martinez FJ, Singh D, Wise R, Lipson DA
doi: 10.1186/s12931-020-01398-w.
Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms; post-hoc analyses of three randomized controlled trials
J Asthma
Kerwin E, Barnes N, Gibbs M, Leather D, Forth R, Jacques L, Yates LJ
doi: 10.1080/02770903.
AsthmaCOPD
Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey
Int J Chron Obstruct Pulmon Dis
Ding B, Small M
doi: 10.2147/COPD.S136314.
RECOMMENDED
COPD
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ther Adv Respir Dis
Marín JM, Mateos L, Roldán J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, Velasco B, Jones CE, Kilbride S, Lipson DA
doi: 10.1177/1753466620963021
RECOMMENDED
COPD
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ther Adv Respir Dis
Vogelmeier CF, Kerwin EM, Bjermer LH, Tombs L, Jones PW, Boucot IH, Naya IP, Lipson DA, Compton C, Barnes N, Maltais F
doi: 10.1177/1753466620968500